Pharmacy Grand Rounds

Pharmacists on the Frontlines: COVID-19 Q&A

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Since the emergence of SARS-CoV-2 pandemic, the practice of pharmacy has been altered to some degree in most, if not all, facets and pharmacists have been engaged in many aspects of the pandemic response.  A panel consisting of pharmacists from a wide range of practice specialties will answer audience questions regarding their experiences in the COVID-19 response including treatment algorithm development, investigational drugs, healthcare incident command response, and patient care in the emergency department, critical care, and pediatric settings.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Describe how pharmacists can be involved in healthcare incident command response to a pandemic
2. Identify medications currently being used and investigated in the treatment of COVID-19 disease
3. Discuss pharmacotherapy treatment considerations in critically ill patients with COVID-19 disease

Session Announcement

Session Slides

FACULTY INFORMATION

Christopher J. Arendt, PharmD
Senior Clinical Manager
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN

Anna S. Bartoo, PharmD
Senior Manager - Pharmacy Research
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN

Laura M. Dinnes, PharmD, BCPPS
Pediatric Clinical Pharmacist
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN

Kirstin Kooda, PharmD, BCPS, BCCCP
Emergency Medicine and Critical Care Pharmacist
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN

Bradley J. Peters, PharmD, BCPS, BCCCP
Emergency Medicine and Critical Care Pharmacist
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN

Ryan W. Stevens, PharmD, BCIDP
Infectious Disease Pharmacist
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN

FACULTY INFORMATION - MODERATORS

Lee P. Skrupky, PharmD, BCPS
Manager - Pharmacy Education
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN

Christina G. Rivera, PharmD, BCPS, AAHIV-P
Infectious Disease Pharmacist
Department of Pharmacy
Mayo Clinic Hospital - Rochester, MN

DISCLOSURE STATEMENTS
As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Christopher J. Arendt, PharmD; Anna S. Bartoo, PharmD; Laura M. Dinnes, PharmD, BCPPS; Kirstin J. Kooda, PharmD, BCPS, BCCCP; Bradley J. Peters, PharmD, BCPS, BCCCP; Ryan W. Stevens, PharmD, BCIDP; Lee P. Skrupky, PharmD, BCPS; Christina G. Rivera, PharmD, BCPS, AAHIV-P
• • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • anakindra
    • canakinumab
    • convalescent plasma
    • eculizumab
    • hydroxychloroquine
    • IVIG
    • lopinavir/ritonavir
    • redesivir
    • sarilumab
    • tocilizumab

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS